CLINICOPATHOLOGICAL FEATURES OF NIGERIANS WITH MYELODYSPLASTIC SYNDROMES

Öz

-

Anahtar Kelimeler

• -

CLINICOPATHOLOGICAL FEATURES OF NIGERIANS WITH MYELODYSPLASTIC SYNDROMES

Öz

Aim: Myelodysplastic syndromes are a group of haematologic disorders characterized by varying degrees of cytopenias and a propensity to leukaemic transformation. The aim of this study is to determine the prevalence, clinical and laboratory characteristics and the outcome of management in Nigerians with this disorder. Methods: Ten patients who have full clinical and laboratory information were retrospectively studied. Data extracted included demographic parameters, clinical features at presentation, haematological parameters, including bone marrow cytology (and cytogenetic findings, where available), management instituted and outcome of such therapy. Results: Ten patients with de novo MDS were managed and followed-up for a median period of 3 months. The majority (90.0%) were aged 50 years or above with a median age of 65 years. All presented with symptoms of cytopenias such as anaemia (100%), neutropenia (50.0%), and thrombocytopenia (10.0%). Patients had mainly supportive management such as blood product supports. One patient, however, in addition received growth factor and cytotoxic chemotherapy, while one received cytotoxic drugs alone. These were however not adequate due to financial constraints. Eight deaths were recorded (88.9%), either cytopenia related (five) or renal failure (three). Cause of death in one was not known as he died at home. The mean survival was 50.5 ± 96.1 weeks (range=2.1–308.4 weeks) Conclusion: It could be concluded that though clinical and laboratory features of Nigerians with MDS are similar to what is obtained from other parts of the world, non-availability of both specific and supportive drugs, and poor socio-economic status of most patients contributed significantly to the poor outcome recorded in this report

Anahtar Kelimeler

• Myelodysplastic syndromes, Presenting features, Nigerian

Kaynakça

1. Lau LG, Chng WJ, Liu TC, et al. Clinico- pathological analysis of myelodysplastic syndromes American-British International Prognostic Scoring System. Ann Acad Med Singapore 2004;33:589- 95 to French- classification and
2. Sokol RJ, Hewitt S, Booker DJ. Erythrocyte autoantibodies, autoimmune haemolysis, syndromes J Clin Pathol 1989;42:1088- 91 myelodysplastic
3. Young NS. Role of the immune system in the pancytopaenia of MDS and immunosuppressive therapy. Haematology 2002;146-50
4. Bennet JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99
5. Harris NL, Jaffe ES, Dieboid J, et al. World Health Organization Classification of Haematopoietic and Lymphoid Tissues. J Clin Oncol;1999;17:3835-49 of the
6. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 1997;89:2079-88
7. Cramer M, Garcia I, Massé J, et al.
8. Erythroblastic Synartesis: An Autoimmune Dyserythropoiesis. Blood 1999;94:3683-93

9. Larson RA. Myelodysplasia: When to treat and how? Best Practice & Res Clin Haematol 2006;19(2):293-300
10. Salawu L., Durosinmi MA. Myelomatosis: clinical and laboratory features in Nigerians. West African J Med 2005;24: 54-7
11. Paul-OdoB, Durosinmi MA, Adediran IA, Akinola NO, Salawu L. Clinical and prognostic features of Nigerians with chronic myeloid leukaemia Nigerian Postgraduate Medical Journal In print
12. Belli C, Acevedo S, Bengio R. et al. Detection of risk groups in myelodysplastic Multicenter study. Haematologica 2002; 87:9-16 syndromes: A
13. Nosslinger T, Reisner R, Koller E, et al. Myelodysplastic syndromes, from French-American-British Health Organisation: comparison of classifications on 431 unselected patients from a single institution. Blood 2001;98: 2935-41 to World
14. Hellstrom-Lindberg E. Update on supportive care and new therapies: immunomodulatory factors and epigenetic-acting agents. Haematology 2005;161-6 growth
15. Balleari E, Rossi E, Clavio M, et al. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-center study. Ann Haematol 2006;85:174-80
16. Zabernigg A, Hilbe W, Eisterer W, Greil R, Ludescher C, Thaler J. Cytokine priming of granulocyte respiratory burst in myelodysplastic syndromes. Leuk Lymphoma 1997;27:137-143
17. Prodan M, Tulissi P, Perticarari S, et al. Flow cytometric assay for the evaluation of phagocytosis and oxidative burst of polymorphonuclear leukocytes and monocytes in myelodysplastic disorders. Haematologica 1995;80:212-8
18. Moretti S, Lanza F, Spisani S, et al. Neutrophils from patients with myelodysplastic syndromes: relationship between impairment of granular contents, complement activities and disease status. Leuk Lymphoma 1994;13:471-7 functional
19. Pomeroy C, Oken MM, Rydell RE, Filice GA. Infection in myelodysplastic syndromes. Am J Med 1991;90:338-44
20. Durosinmi MA, Adediran IA. Cancer management under structural adjustment programme (SAP): Experience in Ile-Ife; Nigeria. Nigerian Med J 1993; 25:92-6
21. Haus O, Kotlarek-Haus S, Potoczek S, et al. Myelodysplastic syndromes according to FAB and WHO classification. Single center experience. Neoplasma 2006;53: 136-43